A Phase 1 clinical study of K 554
Latest Information Update: 30 Dec 2025
At a glance
- Drugs K 554 (Primary)
- Indications Obesity
- Focus Adverse reactions
Most Recent Events
- 30 Dec 2025 New trial record
- 18 Dec 2025 According to the Kallyope media release, K-554, will enter Phase 1 clinical studies in mid-2026.